Our top pick for
NextCure, Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 69 staff and has a trailing 12-month revenue of around USD$24.4 million.
|52-week range||USD$7.91 - USD$44.71|
|50-day moving average||USD$12.5899|
|200-day moving average||USD$10.8283|
|Wall St. target price||USD$23.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.917|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$24.4 million|
|Gross profit TTM||USD$-27,869,000|
|Return on assets TTM||-8.87%|
|Return on equity TTM||-13.42%|
|Market capitalisation||USD$314.7 million|
TTM: trailing 12 months
There are currently 1.9 million NextCure shares held short by investors – that's known as NextCure's "short interest". This figure is 5.5% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting NextCure shares can be evaluated.
NextCure's "short interest ratio" (SIR) is the quantity of NextCure shares currently shorted divided by the average quantity of NextCure shares traded daily (recently around 295587.21461187). NextCure's SIR currently stands at 6.57. In other words for every 100,000 NextCure shares traded daily on the market, roughly 6570 shares are currently held short.
However NextCure's short interest can also be evaluated against the total number of NextCure shares, or, against the total number of tradable NextCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 NextCure shares in existence, roughly 70 shares are currently held short) or 0.0753% of the tradable shares (for every 100,000 tradable NextCure shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NextCure.
Find out more about how you can short NextCure stock.
We're not expecting NextCure to pay a dividend over the next 12 months.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.